Search details
1.
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
Br J Haematol
; 202(1): 40-47, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36971061
2.
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Eur J Haematol
; 109(2): 162-165, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35502609
3.
Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options.
Onco Targets Ther
; 15: 1481-1501, 2022.
Article
in English
| MEDLINE | ID: mdl-36510607
4.
Expression of molecules of the Wnt pathway and of E-cadherin in the etiopathogenesis of human thymomas.
Oncol Lett
; 19(3): 2413-2421, 2020 Mar.
Article
in English
| MEDLINE | ID: mdl-32194741
Results
1 -
4
de 4
1
Next >
>>